KOSP Kos Pharmaceuticals

Kos Pharmaceuticals, Inc. (Nasdaq:KOSP) today announced that Adrian Adams, President and Chief Executive Officer, will present at the UBS Global Life Sciences Conference, which is being held September 25 - September 28, 2006 in New York, NY. Kos' presentation will take place at 1:30 p.m. ET on Monday, September 25, 2006. Interested parties can access the webcast information by going to the investor relations section of Kos' website at www.kospharm.com, and referencing upcoming events. About Kos Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases with a particular focus on the cardiovascular, metabolic and respiratory disease areas. The Company's principal product development strategy is to reformulate existing pharmaceutical products with large market potential to improve safety, efficacy, and patient compliance. Kos' strategy also includes making measured investments in new chemical entity research through in-house and sponsored research, scientific in-licensing and general corporate development activities. The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R) and Teveten(R)HCT.